GlassScriptPhysician profile
Deborah A Fein
NPI 1013998210
$4,041.01
in general payments reported to CMS, 2019-2025
31 companies · $1,208 in 2025
The $1,208 reported for 2025 was more than what 82% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $641 · 2020: $67.89 · 2021: $18.99 · 2022: $60.19 · 2023: $759 · 2024: $1,286 · 2025: $1,208.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,184 · Education: $68.41.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,184.45 |
| Education | $68.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $400.65 | 2019-2025 | Jynarque |
| Fresenius USA Marketing, INC. | $351.89 | 2019-2025 | Velphoro, Velphoro |
| Astrazeneca Pharmaceuticals LP | $351.40 | 2019-2025 | Farxiga, Lokelma |
| Amgen INC. | $348.35 | 2019-2025 | Tavneos, Parsabiv, Aranesp |
| Travere Therapeutics, INC. | $296.85 | 2024-2025 | Filspari |
| Novartis Pharmaceuticals Corporation | $274.98 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $269.26 | 2022-2025 | |
| Calliditas Therapeutics US INC. | $253.73 | 2023-2025 | Tarpeyo |
| Ardelyx, INC. | $250.42 | 2024-2025 | Xphozah 30 Mg, Ibsrela |
| Vifor Pharma, INC. | $149.33 | 2019-2024 | Veltassa, Korsuva |
| E.R. Squibb & Sons, L.L.C. | $126.63 | 2025 | Cobenfy |
| Bard Peripheral Vascular, INC. | $125.00 | 2019 | |
| Opko Pharmaceuticals, LLC | $112.91 | 2019-2024 | Rayaldee |
| Akebia Therapeutics INC | $105.72 | 2019-2020 | |
| Novo Nordisk INC | $99.51 | 2019-2024 | Wegovy, Rybelsus, Ozempic |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $97.99 | 2023-2024 | Benlysta, Jesduvroq, Shingrix |
| Janssen Pharmaceuticals, INC | $89.37 | 2019-2020 | |
| Aurinia Pharma U.S., INC. | $86.03 | 2024-2025 | Lupkynis |
| Lilly USA, LLC | $53.34 | 2019-2023 | Mounjaro |
| Horizon Therapeutics Plc | $27.70 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $18.99 | 2021 | |
| Renalytix Ai, INC. | $17.90 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Ani Pharmaceuticals, INC. | $17.33 | 2023 | Purified Cortrophin Gel |
| Pfizer INC. | $16.75 | 2024 | |
| Sanofi Pasteur INC. | $15.44 | 2023 | |
| Xeris Pharmaceuticals, INC. | $14.91 | 2023 | Keveyis |
| Strongbridge US INC. | $14.86 | 2020 | |
| Apellis Pharmaceuticals, INC. | $14.75 | 2025 | Empaveli |
| Mallinckrodt Enterprises LLC | $14.35 | 2019 | |
| Merck Sharp & Dohme LLC | $12.50 | 2019 | |
| Arbor Pharmaceuticals, INC. | $12.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Fein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.